The Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial (CATT) was a multicenter clinical trial that compared the relative safety and effectiveness of two drugs currently used to treat advanced age-related macular degeneration (AMD).
NEI released the second year results in April 2012. The CATT trial found that Avastin (bevacizumab) and Lucentis (ranibizumab) are equivalent in treating age-related macular degeneration. They both improve vision when given monthly or on an as needed basis. Monthly injections showed greater improvements in vision.
For all of the NEI information on this topic, please visit the following webpages:
Avastin and Lucentis are equivalent in treating age-related macular degeneration
Comparison of AMD Treatments Trials (CATT): Lucentis - Avastin Trial
Age-Related Macular Degeneration
Facts About Age-Related Macular Degeneration